BOARD OF DIRECTORS

Houman Ashrafian

Executive Chair

Houman Ashrafian
Executive Chair
Houman Ashrafian is Managing Partner at SV. He joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded five SV companies; Sitryx, Enara Bio, Zarodex, TrexBio and Alchemab. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and as a Director of Karus Therapeutics.
 Previously, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. Heart Metabolics successfully repositioned perhexiline, as a treatment for hypertrophic cardiomyopathy and heart failure. Perhexiline is now in advanced clinical trials and has orphan drug designation. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma.

Kate Bingham

Board Member

Kate Bingham
Board Member
Kate Bingham is Managing Partner at SV and responsible for biotech investments and activities in the UK and EU. Her investments include small-molecule, biotherapeutic and gene therapy drug discovery and development projects as well as drug discovery platforms in a broad range of clinical areas. In her 29 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer. She played an active role in setting up the Dementia Discovery Fund (DDF), an SV managed fund, and currently serves on the DDF Investment Committee. Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals and at Monitor Company, a strategy consulting firm. Kate won the 2017 Lifetime Achievement Award, presented by BioIndustry Association UK. She also serves on the Board of the Francis Crick Institute and sits on the Advisory Committee of Oxford University Spin-out Equity Management (OSEM).

Neil Weir

Board Member

Neil Weir
Board Member
Neil Weir is CEO of Sitryx, a biotech in the field of immunometabolism. Prior to Sitryx, Neil was Senior Vice-President, Discovery, at UCB S.A. overseeing an integrated portfolio of small molecule and antibody projects immunology and neurology. Neil and his teams transitioned 33 new chemical entities into development in immunology, oncology, bone and neurology including the marketed medicines Cimzia, Besponsa and Romosozumab. Neil was an inventor of Cimzia® and dual signalling domain chimeric receptors now known as second generation CAR-Ts. Neil served as chair of the board of Beryllium BioSciences in Boston and as a non-exec member of the boards of the RNA Medicines company (Boston) and Ondek (Perth WA). Neil chaired the UK ABPI innovation board from 2012 to 2018, has been involved in various MRC advisory board positions and was a member of the steering board for the German federal government’s Neuroallianz consortium.

Susan Hill

Chief Executive Officer

Susan Hill
Chief Executive Officer
Susan Hill is Chief Executive Officer of Mestag Therapeutics. Susan joined Mestag from clinical complement company Gyroscope Therapeutics, where she served as Chief Business Officer and helped to drive the company’s $62m Series B. Prior, she was founding Chief Executive Officer of Orbit Biomedical ($12m Series A) and Chief Business Officer of Freeline Therapeutics. Previously, Susan served in the Business & Corporate Development team at Alexion (ALXN), and during an 8-year tenure at Merck Serono (MRK) in a series of Corporate & Business Development and Portfolio Management roles. Susan began her career in strategy consulting/M&A, followed by a 3-year tenure leading biotech seed investments.  She has an MA and PhD from the University of Cambridge and is a previous Fellow of the Securities Institute.

Fiona MacLaughlin

Board Member

Fiona MacLaughlin
Board Member
Fiona is a Senior Director, Venture Investments, at Johnson & Johnson Development Corporation (JJDC). Prior to joining JJDC, Fiona served as a Director at Inkef Capital, where she led both pharma and MedTech investments and held Board seats in a number of portfolio companies. A qualified pharmacist, Fiona is passionate about helping early-stage companies establish a value-building trajectory by engaging and challenging management and creating optimal development plans. Fiona began her career in biotech focusing on the development of non-viral gene therapy and other novel delivery solutions. A fundamental interest in philanthropy led her to the Wellcome Trust and a focus on translational funding, including establishing a fund to support the development of affordable healthcare technologies in India. Fiona’s transition to venture investing began with a move to Advent Life Sciences, where she was involved in helping shape and build a number of early-stage companies including Arrakis Therapeutics.

Juliette Audet

Board Member

Juliette Audet
Board Member
Juliette Audet is Partner at Forbion in the Naarden office and joined the Forbion team in 2019. She currently serves as a board member for NewAmsterdam Pharma and Mestag Therapeutics. Prior to joining Forbion, Juliette was a Principal at the Novartis Venture Fund based in Cambridge (USA). There she sat on the boards of TScan Therapeutics and Annexon Biosciences as an observer. Juliette was also leading the management NVF’s public equities. Before that, Juliette was a Senior Manager of Strategy at Novartis AG, where she worked with the senior executive team of the Pharma division. Juliette spent the first years of her career in management consulting at McKinsey and Company focusing on Pharma and Biotech, based out of the Swiss and then New York offices. Juliette graduated with distinction from Harvard Business School in 2015 (MBA) and received her MSc in Physics (Suma Cum Laude) from EPFL (Lausanne, Swiss Federal Institute of Technology) in 2010.

Shaan C. Gandhi

Board Member

Shaan C. Gandhi
Board Member
Shaan C. Gandhi is a Director at Northpond Ventures and leads the firm’s work in biotechnologies. Shaan is a board director at Mestag Therapeutics, as well as several other private and public biotherapeutics companies. Previously, Shaan was a Principal at the Longwood Fund, where he created and invested in life sciences companies, including Pyxis Oncology, a cancer immunotherapy company focused on novel modulators of the tumor microenvironment, which he co-founded and served as President. Prior to Longwood, he was an attending hospitalist at Massachusetts General Hospital, where he also did his residency in internal medicine. He holds an MD from Harvard Medical School; an MBA from Harvard Business School, where he was a Baker Scholar; a D.Phil. in medical oncology from the University of Oxford, where he was a Rhodes Scholar; and a B.S. with honors in biochemistry from Case Western Reserve University. Shaan is the Secretary/Treasurer of the Suffolk District Medical Society, the professional medical society of Boston, and a Trustee of the Boston Medical Library.

Issi Rozen

Board Member

Issi Rozen
Board Member
Issi Rozen is a Venture Partner at GV, where he primarily focuses on the formation of new companies and early-stage investments. Issi is an experienced biotech executive and a serial entrepreneur who co-founded multiple startups, including GV portfolio company Verve Therapeutics. Previously, Issi spent a decade at the Broad Institute of MIT and Harvard, where he was the Institute’s first Chief Business Officer and a member of the Executive Leadership Team. At the Broad, Issi led the creation of the Office of Strategic Alliances and Partnering and was responsible for developing innovative scientific and business collaborations, initiating and establishing new ventures around novel technologies, and overseeing strategy and licensing of the Institute’s intellectual property portfolio. Issi played a key role in the creation and spin-out of over 20 startups from the Institute. Prior to joining the Broad, Issi led strategy and business development efforts at a number of biotech companies. An accomplished jazz guitarist, Issi is also a former professor at Berklee College of Music. He earned his M.B.A. at MIT’s Sloan School of Management.